Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity

CD47 serves as an anti-phagocytic receptor that is upregulated by cancer to promote immune escape. As such, CD47 is the focus of intense immuno-oncology drug development efforts. However, as CD47 is expressed ubiquitously, clinical development of conventional drugs, e.g., monoclonal antibodies, is c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dheilly, Elie, Majocchi, Stefano, Moine, Valéry, Didelot, Gérard, Broyer, Lucile, Calloud, Sébastien, Malinge, Pauline, Chatel, Laurence, Ferlin, Walter G., Kosco-Vilbois, Marie H., Fischer, Nicolas, Masternak, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698848/
https://www.ncbi.nlm.nih.gov/pubmed/31544856
http://dx.doi.org/10.3390/antib7010003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698848/
https://www.ncbi.nlm.nih.gov/pubmed/31544856
http://dx.doi.org/10.3390/antib7010003

Ejemplares similares